HEMAPHERESIStitle

Donor safety in triple plateletpheresis: results from the German and Austrian Plateletpheresis Study Group multicenter trial

Corresponding Author

Hans-Gert Heuft

From the Institute for Transfusion Medicine, Hannover Medical School, Hannover, Germany; the Hospital Laboratory Network Brandenburg-Berlin, Bernau, Germany; Aix Scientifics, Clinical Research Organisation, Aachen, Germany; and the Department for Transfusion Medicine& Hemostaseology, University Hospital Erlangen, Erlangen, Germany.

Hans-Gert Heuft, Institute for Transfusion Medicine, Hannover Medical School, Carl Neuberg Strasse 1, D-30625 Hannover, Germany; e-mail: [email protected].Search for more papers by this author

Rainer Moog,

Rainer Moog

Search for more papers by this author

Eike G. Fischer,

Eike G. Fischer

Search for more papers by this author

Jürgen Zingsem,

Jürgen Zingsem

Search for more papers by this author

German and Austrian Plateletpheresis Study Group,

German and Austrian Plateletpheresis Study Group

Search for more papers by this author

Hans-Gert Heuft,

Corresponding Author

Hans-Gert Heuft

Hans-Gert Heuft, Institute for Transfusion Medicine, Hannover Medical School, Carl Neuberg Strasse 1, D-30625 Hannover, Germany; e-mail: [email protected].Search for more papers by this author

Rainer Moog,

Rainer Moog

Search for more papers by this author

Eike G. Fischer,

Eike G. Fischer

Search for more papers by this author

Jürgen Zingsem,

Jürgen Zingsem

Search for more papers by this author

German and Austrian Plateletpheresis Study Group,

German and Austrian Plateletpheresis Study Group

Search for more papers by this author

First published: 21 May 2012

https://doi.org/10.1111/j.1537-2995.2012.03714.x

Citations: 15

The study was financed by grants from Baxter Deutschland GmbH, Unterschleißheim, Germany; Fresenius Transfusions GmbH, Friedberg, Germany; Gambro BCT, Zaventem, Belgium; and Haemonetics Deutschland GmbH, Munich, Germany.

Share a link

Email
Wechat
Bluesky

Abstract

BACKGROUND: The objective was to investigate potential risks for apheresis donors associated with a triple-plateletpheresis (TP) program.

STUDY DESIGN AND METHODS: Eleven hemapheresis centers randomly assigned 411 repeat donors (ratio, 1:1.2) to either double plateletpheresis (DP; 185 donors) or TP (226 donors) with a platelet (PLT) target content of at least 5.0 × 10¹¹ PLTs/DP and at least 7.5 × 10¹¹ PLTs/TP. The primary endpoint was procedure-related postapheresis PLT count of at least 150 × 10⁹/L (probability, ≥98%). Secondary endpoints were apheresis characteristics and donor adverse reactions.

RESULTS: In 6 of 1133 DPs (0.5%) in 4 of 185 donors (2.2%) and in 20 of 1020 TPs (2.0%) in 14 of 226 donors (6.2%), postapheresis PLT counts were below 150 × 10⁹/L. There were marginal but significant differences in collection efficiency (DP, 69.2 ± 9.1%; TP, 70.9 ± 9.0%; p ≤ 0.0001) and collection rate (DP, 10.4 × 10⁹ ± 2.3 × 10⁹ PLTs/min; TP, 10.8 × 10⁹ ± 2.3 × 10⁹ PLTs/min; p ≤ 0.005). The PLT yields were 5.9 × 10¹¹ ± 0.8 × 10¹¹ PLTs for DP and 8.3 × 10¹¹ ± 0.9 × 10¹¹ PLT for TP (p ≤ 0.0001) at processing times of 59 ± 13 minutes (DP) versus 80 ± 16 minutes (TP; p ≤ 0.0001). Significant PLT recruitment (1.10 ± 0.14 vs. 1.20 ± 0.23; p < 0.0001) was seen for both DP and TP. DP and TP did not differ with regard to venous access problems (VAPs) without discontinuation (3.8% for both), but DP induced fewer VAPs with discontinuation (1.1% vs. 3.0%; p < 0.01). Mild citrate toxicity (1.7% vs. 3.9%; p < 0.01) and circulatory reactions (0.4% vs. 2.2%; p < 0.01) were more often noticed in TP, but caused no increase in discontinuations.

CONCLUSIONS: TP results in an increase in mild donor reactions but does not significantly impair donor safety or product quality.

REFERENCES

1 Valbonesi AM, Florio G, Venturino V, Bruni R. Plateletpheresis: what's new? Transfus Sci 1996; 17: 537-44.
10.1016/S0955-3886(96)90089-2
CAS PubMed Web of Science® Google Scholar
2 Murphy MF, Seghatchian J, Krailadsiri P, Howell C, Verjee S. Evaluation of Cobe Trima for the collection of blood components with particular reference to the in vitro characteristics of the red cell and platelet concentrates and the clinical responses to transfusion. Transfus Sci 2000; 22: 39-43.
10.1016/S0955-3886(00)00006-0
CAS PubMed Web of Science® Google Scholar
3 Moog R, Zeiler T, Heuft HG, Stephan B, Fischer EG, Kretschmer V, Rodel-Spiecker R, Strasser E, Zingsem J. Collection of WBC-reduced single-donor PLT concentrates with a new blood cell separator: results of a multicenter study. Transfusion 2003; 43: 1107-14.
10.1046/j.1537-2995.2003.00467.x
PubMed Web of Science® Google Scholar
4 Ringwald J, Zingsem J, Zimmermann R, Strasser E, Antoon M, Eckstein R. First comparison of productivity and citrate donor load between the Trima version 4 (dual-stage filler) and the Trima Accel (single-stage filler) in the same donors. Vox Sang 2003; 85: 267-75.
10.1111/j.0042-9007.2003.00370.x
CAS PubMed Web of Science® Google Scholar
5 Zingsem J. Multicomponent apheresis. ISBT Sci Ser 2010; 5: 83-7.
10.1111/j.1751-2824.2010.01400.x
Web of Science® Google Scholar
6 Picker SM, Radojska SM, Gathof BS. Evaluation of concurrent collection of in-line filtered platelets and packed red blood cells by multicomponent apheresis with three last-generation apparatuses. Vox Sang 2006; 91: 47-55.
10.1111/j.1423-0410.2006.00774.x
CAS PubMed Web of Science® Google Scholar
7 Strauss RG. Risks of clinically significant thrombocytopenia and/or lymphocytopenia in donors after multiple plateletpheresis collections. Transfusion 2008; 48: 1274-8.
10.1111/j.1537-2995.2008.01785.x
PubMed Web of Science® Google Scholar
8 Lazarus EF, Browning J, Norman J, Oblitas J, Leitman SF. Sustained decreases in platelet count associated with multiple, regular plateletpheresis donations. Transfusion 2001; 41: 756-61.
10.1046/j.1537-2995.2001.41060756.x
CAS PubMed Web of Science® Google Scholar
9 Fontana S, Mordasini L, Keller P, Taleghani BM. Prospective, paired crossover comparison of multiple, single-needle plateletpheresis procedures with the Amicus and Trima Accel cell separators. Transfusion 2006; 46: 2004-10.
10.1111/j.1537-2995.2006.01009.x
CAS PubMed Web of Science® Google Scholar
10 Picker SM, Radojska SM, Gathof BS. Prospective comparison of high-dose plateletpheresis with the latest apheresis systems on the same donors. Transfusion 2006; 46: 1601-8.
10.1111/j.1537-2995.2006.00928.x
CAS PubMed Web of Science® Google Scholar
11 Richa E, Krueger P, Burgstaler E, Bryant S, Winters J. The effect of double and triple apheresis platelet product donation on apheresis donor platelet and white blood cell counts. Transfusion 2008; 48: 1325-32.
10.1111/j.1537-2995.2008.01669.x
CAS PubMed Web of Science® Google Scholar
12 Katz L, Palmer K, McDonnell E, Kabat A. Frequent plateletpheresis does not clinically significantly decrease platelet counts in donors. Transfusion 2007; 47: 1601-6.
10.1111/j.1537-2995.2007.01330.x
CAS PubMed Web of Science® Google Scholar
13 Council of Europe. Guide to the preparation, use and quality assurance of blood components. 12th ed. Strasbourg: Council of Europe; 2006. p. 48.
Google Scholar
14 German Medical Association and the Paul-Ehrlich-Institute. Guidelines for the collection of blood and blood components and to the usage of blood products. Köln, Germany: Deutscher Ärzte-Verlag; 2010. p. 26-7f.
Google Scholar
15 Slichter SJ, Kaufman RM, Assmann SF, McCullough J, Triulzi DJ, Strauss RG, Gernsheimer TB, Ness PM, Brecher ME, Josephson CD, Konkle BA, Woodson RD, Ortel TL, Hillyer CD, Skerrett DL, McCrae KR, Sloan SR, Uhl L, George JN, Aquino VM, Manno CS, McFarland JG, Hess JR, Leissinger C, Granger S. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 2010; 362: 600-13.
10.1056/NEJMoa0904084
CAS PubMed Web of Science® Google Scholar
16 Moog R. Feasibility and safety of triple dose platelet collection by apheresis. J Clin Apher 2009; 24: 238-40.
10.1002/jca.20221
CAS PubMed Web of Science® Google Scholar
17 Heuft HG, Goudeva L, Peine S, Martens J, Schmitt-Thomssen A, Blasczyk R. Routine collection of triple platelet components using two different apheresis systems [abstract]. Transfus Med Hemother 2005; 32: 26.
Google Scholar
18 Heuft HG, Goudeva L, Martens J, Schmitt-Thomssen A, Blasczyk R. The mobilization effect of platelet apheresis [abstract]. Transfus Med Hemother 2006; 33: 17.
Google Scholar
19 Axelrod FB. The growing practice of splitting double dose apheresis platelet products. Transfus Sci 1993; 14: 364-8.
10.1016/S0955-3886(05)80008-6
CAS PubMed Web of Science® Google Scholar
20 Fontana S, Keller P, Mansouri Taleghani B. Platelet recruitment during multiple donor platelet apheresis differs between cell separators. Transfus Med Hemother 2011; 38: 195-8.
10.1159/000328634
PubMed Web of Science® Google Scholar
21 Winters JL. Complications of donor apheresis. J Clin Apher 2006; 21: 132-41.
10.1002/jca.20039
PubMed Web of Science® Google Scholar
22 Bueno JL, Castro E, García F, Barea L, González R. Hematomas in multicomponent apheresis: searching for related factors. Transfusion 2006; 46: 2184-91.
10.1111/j.1537-2995.2006.01050.x
PubMed Web of Science® Google Scholar
23 Makar YF, Butler MO, Cockersole GM, Gabra G, Serevitch JM. National audit of citrate toxicity in plateletpheresis donors. Transfus Med 2002; 12: 187-91.
10.1046/j.1365-3148.2002.00372.x
PubMed Web of Science® Google Scholar
24 McLeod BC, Price TH, Owen H, Ciavarella D, Sniecinski I, Randels MJ, Smith JW. Frequency of immediate adverse effects associated with apheresis donation. Transfusion 1998; 38: 938-43.
10.1046/j.1537-2995.1998.381098440858.x
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume53, Issue1

January 2013

Pages 211-220

Donor safety in triple plateletpheresis: results from the German and Austrian Plateletpheresis Study Group multicenter trial

Abstract

REFERENCES

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Donor safety in triple plateletpheresis: results from the German and Austrian Plateletpheresis Study Group multicenter trial

Abstract

REFERENCES

Citing Literature

References

Related

Information